<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article245</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/Ibrutinib_in_Waldenstrom_macroglobulinemia" style="display:block; margin-bottom:10px;">Ibrutinib in Waldenstrom macroglobulinemia Original</a></li>
<h2><strong>Ibrutinib in Waldenstrom macroglobulinemia</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Ibrutinib for Previously Treated Waldenström's Macroglobulinemia". <br/>
The New England Journal of Medicine. 2015. <br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
<br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcomes<br/>
8.2 Secondary Outcomes<br/>
9 Funding<br/>
10 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does ibrutinib improve clinical outcomes in symptomatic patients with previously treated Waldenström's macroglobulinemia?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In previously treated patients with Waldenström's macroglobulinemia, ibrutinib was effective in achieving a high overall response rate of 90.5% and promoting durable responses with a 2-year progression-free-survival rate of 69.1%.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
Waldenström's macroglobulinemia is a malignant B-cell lymphoma with limited treatment options upon progression. Ibrutinib, a Bruton's tyrosine kinase inhibitor, has proven to be a promising therapy due to the high prevalence of MYD88L265P mutation that activates tumor-cell growth via Bruton's tyrosine kinase pathway. CXCR4WHIM mutations confer in vitro resistance to ibrutinib, thus creating a need to understand the impact of these mutations on treatment outcomes.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of 2015, no guidelines have been published that reflect the results of this trial for the use of ibrutinib in Waldenström's macroglobulinemia.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Prospective, multicenter study of 63 symptomatic patients with previously treated Waldenström's macroglobulinemia.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
<br/>
Inclusion Criteria<br/>
Symptomatic patients requiring treatment, one or more prior regiments, adequate counts, no central nervous system involvement, no significant cardiovascular disease.<br/>
<br/>
Exclusion Criteria<br/>
Central nervous system lymphoma, significant cardiovascular disease, use of warfarin, or medications prolonging the QT interval.<br/>
<br/>
Baseline Characteristics<br/>
Patients had received a median of two prior therapies. Baseline MYD88L265P mutation present in 89%, CXCR4WHIM in 34%. <br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
420 mg of ibrutinib orally per day for up to twenty-six 4-week cycles, with further treatment continuation upon re-consent.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
<br/>
Primary Outcomes<br/>
Overall response rate was 90.5%, with a major response rate of 73.0%. Median serum IgM levels decreased and hemoglobin levels increased significantly.<br/>
<br/>
Secondary Outcomes<br/>
Estimated 2-year progression-free survival was 69.1%, with an overall survival rate of 95.2%. Responses were highest among patients with MYD88L265P and wild-type CXCR4 genotype.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
The study was supported by Pharmacyclics, Janssen Pharmaceuticals, various foundations, and private donations.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
Full details and supplemental material can be accessed at the NEJM with ClinicalTrials.gov number NCT01614821.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
